Live Breaking News & Updates on நல்ல ஆய்வகம் ப்ர்யாக்டிஸஸ்

Stay updated with breaking news from நல்ல ஆய்வகம் ப்ர்யாக்டிஸஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Paradigm Biopharmaceuticals Ltd receives written feedback from FDA relating to IND submission


Paradigm Biopharmaceuticals receives written feedback from FDA relating to IND submission
Pentosan polysulfate sodium (PPS) is currently being evaluated by Paradigm for potential registration for the treatment of osteoarthritis and other inflammatory diseases in the US and other major global markets.
The FDA response requires further clarification on one remaining question.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received written feedback from the US Food and Drug Administration (FDA) on July 30, 2021 regarding Paradigm’s Investigational New Drug (IND) application submitted on March 26, 2021.
The company previously reported it had received written feedback from the US FDA, requesting answers to six questions relating to Paradigm’s IND submission. ....

Donna Skerrett , Good Laboratory Practices , Drug Administration , Investigational New Drug , Paradigm Biopharmaceuticals , நல்ல ஆய்வகம் ப்ர்யாக்டிஸஸ் , முன்னுதாரணம் உயிர் மருந்துகள் ,